Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Sinopharm Group Co's share price for the quarter that ended in Jun. 2024 was HK$20.75. Sinopharm Group Co's Shares Outstanding (EOP) for the quarter that ended in Jun. 2024 was 3,121 Mil. Therefore, Sinopharm Group Co's market cap for the quarter that ended in Jun. 2024 was HK$64,754 Mil.
Sinopharm Group Co's quarterly market cap
declined
from Jun. 2023 (HK$76,456 Mil) to Dec. 2023 (HK$63,817 Mil) but then
increased
from Dec. 2023 (HK$63,817 Mil) to Jun. 2024 (HK$64,754 Mil).
Sinopharm Group Co's annual market cap
increased
from Dec. 2021 (HK$52,926 Mil) to Dec. 2022 (HK$61,914 Mil) and
increased
from Dec. 2022 (HK$61,914 Mil) to Dec. 2023 (HK$63,817 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Sinopharm Group Co's Enterprise Value for Today is HK$128,056 Mil.
Sinopharm Group Co Market Cap Historical Data
The historical data trend for Sinopharm Group Co's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Sinopharm Group Co's Market Cap
For the Medical Distribution subindustry, Sinopharm Group Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinopharm Group Co's Market Cap Distribution in the Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's Market Cap distribution charts can be found below:
* The bar in red indicates where Sinopharm Group Co's Market Cap falls into.
Sinopharm Group Co Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Sinopharm Group Co's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinopharm Group Co (HKSE:01099) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Sinopharm Group Co Market Cap Related Terms
Thank you for viewing the detailed overview of Sinopharm Group Co's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2023. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:01099 has been successfully added to your 